$ERAS
Erasca, Inc.

2023 Q4 Form 10-Q Financial Statement

#000095017023062094 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.067M $9.450M
YoY Change 3.96% 7.66%
% of Gross Profit
Research & Development $24.81M $25.21M
YoY Change -15.5% -10.54%
% of Gross Profit
Depreciation & Amortization $942.0K $941.0K
YoY Change 0.96% 22.05%
% of Gross Profit
Operating Expenses $33.87M $34.66M
YoY Change -11.05% -6.23%
Operating Profit -$34.66M
YoY Change -6.23%
Interest Expense $4.238M $4.346M
YoY Change 47.26% 185.55%
% of Operating Profit
Other Income/Expense, Net -$67.00K $4.297M
YoY Change 34.0% 191.72%
Pretax Income -$29.70M -$30.36M
YoY Change -78.04% -14.45%
Income Tax
% Of Pretax Income
Net Earnings -$29.70M -$30.36M
YoY Change -78.04% -14.45%
Net Earnings / Revenue
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20 -$0.20
COMMON SHARES
Basic Shares Outstanding 151.1M 151.0M
Diluted Shares Outstanding 150.5M

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $312.4M $296.7M
YoY Change -28.3% -16.64%
Cash & Equivalents $93.08M $112.9M
Short-Term Investments $219.3M $183.8M
Other Short-Term Assets $8.326M $9.300M
YoY Change -6.2% -5.32%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $320.7M $306.0M
YoY Change -27.86% -16.35%
LONG-TERM ASSETS
Property, Plant & Equipment $60.19M $23.23M
YoY Change 142.55% -6.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $9.642M $46.90M
YoY Change 390.12%
Other Assets $4.791M $4.388M
YoY Change 0.4% -8.1%
Total Long-Term Assets $74.62M $113.4M
YoY Change 5.98% 40.61%
TOTAL ASSETS
Total Short-Term Assets $320.7M $306.0M
Total Long-Term Assets $74.62M $113.4M
Total Assets $395.3M $419.4M
YoY Change -23.23% -6.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.000M $3.701M
YoY Change -91.32% -14.31%
Accrued Expenses $23.69M $22.40M
YoY Change -1.08% 4.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $26.16M $26.73M
YoY Change -46.28% -3.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $52.46M $761.0K
YoY Change 9054.45% -98.58%
Total Long-Term Liabilities $52.46M $761.0K
YoY Change 9054.45% -98.58%
TOTAL LIABILITIES
Total Short-Term Liabilities $26.16M $26.73M
Total Long-Term Liabilities $52.46M $761.0K
Total Liabilities $78.61M $80.43M
YoY Change -23.72% -0.84%
SHAREHOLDERS EQUITY
Retained Earnings -$606.0M -$576.3M
YoY Change 25.99% 66.71%
Common Stock $922.6M $915.9M
YoY Change 3.22% 28.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $316.7M $339.0M
YoY Change
Total Liabilities & Shareholders Equity $395.3M $419.4M
YoY Change -23.23% -6.05%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$29.70M -$30.36M
YoY Change -78.04% -14.45%
Depreciation, Depletion And Amortization $942.0K $941.0K
YoY Change 0.96% 22.05%
Cash From Operating Activities -$24.79M -$24.12M
YoY Change -6.01% 0.73%
INVESTING ACTIVITIES
Capital Expenditures $85.00K $240.0K
YoY Change -90.16% -113.39%
Acquisitions
YoY Change
Other Investing Activities $4.625M -$1.570M
YoY Change -215.54% -97.06%
Cash From Investing Activities $4.550M -$1.820M
YoY Change -193.49% -96.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 455.0K 10.00K
YoY Change -99.53% -97.66%
NET CHANGE
Cash From Operating Activities -24.79M -24.12M
Cash From Investing Activities 4.550M -1.820M
Cash From Financing Activities 455.0K 10.00K
Net Change In Cash -19.78M -25.93M
YoY Change -130.45% -67.07%
FREE CASH FLOW
Cash From Operating Activities -$24.79M -$24.12M
Capital Expenditures $85.00K $240.0K
Free Cash Flow -$24.87M -$24.36M
YoY Change -8.68% 9.96%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001761918
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40602
dei Entity Registrant Name
EntityRegistrantName
ERASCA, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1217027
dei Entity Address Address Line1
EntityAddressAddressLine1
3115 Merryfield Row
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
465-6511
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
ERAS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
151087038
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112862000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
284217000
CY2023Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
183806000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
151403000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9298000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
8876000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
305966000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
444496000
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
46891000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23229000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24815000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38524000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
40418000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
408000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
408000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4388000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4772000
CY2023Q3 us-gaap Assets
Assets
419406000
CY2022Q4 us-gaap Assets
Assets
514909000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3701000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
23049000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19211000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24336000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3818000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1305000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
26730000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
48690000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52940000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
53793000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
761000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
573000
CY2023Q3 us-gaap Liabilities
Liabilities
80431000
CY2022Q4 us-gaap Liabilities
Liabilities
103056000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
80000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
80000000
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
800000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
151053118
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
150448363
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
150537752
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
149333258
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
915847000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
893850000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-575000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1041000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-576312000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-480971000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
338975000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
411853000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
419406000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
514909000
CY2023Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
25213000
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
28184000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
79016000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
83101000
eras In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
2000000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9445000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8778000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
28637000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
24271000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
34658000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
36962000
us-gaap Operating Expenses
OperatingExpenses
107653000
us-gaap Operating Expenses
OperatingExpenses
109372000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-34658000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-36962000
us-gaap Operating Income Loss
OperatingIncomeLoss
-107653000
us-gaap Operating Income Loss
OperatingIncomeLoss
-109372000
CY2023Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4346000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1522000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
12474000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2024000
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
49000
CY2022Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
49000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
162000
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
207000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4297000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1473000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
12312000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1817000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-30361000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35489000
us-gaap Net Income Loss
NetIncomeLoss
-95341000
us-gaap Net Income Loss
NetIncomeLoss
-107555000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150450201
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150450201
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120798322
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120798322
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
150000613
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150000613
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
120166023
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120166023
CY2023Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
218000
CY2022Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-156000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
466000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1217000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-30143000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35645000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94875000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108772000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
411853000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
183000
CY2023Q1 eras Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
243000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6845000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-33199000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
527000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
386452000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
122000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
527000
CY2023Q2 eras Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
652000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7012000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-31781000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-279000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
362705000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000
CY2023Q3 eras Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
168000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6238000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-30361000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
218000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
338975000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
456528000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
460000
CY2022Q1 eras Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
479000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4442000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36458000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-789000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
424662000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
375000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
617000
CY2022Q2 eras Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
238000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5055000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-35608000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-272000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
395067000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
427000
CY2022Q3 eras Stock Issued During Period Value Vesting Of Early Exercised Stock Options
StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions
238000
eras Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
1063000
eras Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
955000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
22704000
eras Reduction In Operating Lease Assets Due To Lease Amendment
ReductionInOperatingLeaseAssetsDueToLeaseAmendment
3361000
CY2023Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
296700000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5232000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35489000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-156000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
365319000
us-gaap Profit Loss
ProfitLoss
-95341000
us-gaap Profit Loss
ProfitLoss
-107555000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2790000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1708000
us-gaap Share Based Compensation
ShareBasedCompensation
20095000
us-gaap Share Based Compensation
ShareBasedCompensation
14729000
eras In Process Research And Development Expense
InProcessResearchAndDevelopmentExpense
2000000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4756000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
169000
eras Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
38000
eras Increase Decrease In Prepaid Expenses And Other Current And Long Term Assets
IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAndLongTermAssets
4512000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
777000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1540000
eras Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
-3253000
eras Increase Decrease In Accrued Expenses And Other Current And Long Term Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentAndLongTermLiabilities
2936000
eras Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
-3297000
eras Increase Decrease In Operating Lease Assets And Liabilities Net
IncreaseDecreaseInOperatingLeaseAssetsAndLiabilitiesNet
-12431000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76429000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76892000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
253272000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
94427000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
179200000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45900000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
20000000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
2000000
us-gaap Payments To Acquire Equity Securities Fv Ni
PaymentsToAcquireEquitySecuritiesFvNi
2000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1693000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13687000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-95765000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-66214000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
312000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1262000
eras Proceeds From Issuance Of Common Stock Under The Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan
527000
eras Proceeds From Issuance Of Common Stock Under The Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTheEmployeeStockPurchasePlan
617000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
839000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1879000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-171355000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-141227000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
284625000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
360895000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
113270000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
219668000
eras Amounts Accrued For Purchase Of Property And Equipment
AmountsAccruedForPurchaseOfPropertyAndEquipment
54000
eras Amounts Accrued For Purchase Of Property And Equipment
AmountsAccruedForPurchaseOfPropertyAndEquipment
841000
CY2023Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
46900000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-576300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Arial;min-width:fit-content;">The preparation of the Company’s condensed consolidated financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities, expenses, and the disclosure of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. Accounting estimates and management judgments reflected in the condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses, fair value of common stock, stock-based compensation expense, and the incremental borrowing rate for determining the operating lease asset and liability. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></p>
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
408000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
408000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
582000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
230697000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
152444000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1047000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
151403000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112862000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
219260000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
408000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
408000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113270000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
219668000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
231272000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
7000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
189601000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
544000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
9960000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
38000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
199561000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
582000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
63851000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
143000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
44048000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
904000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
107899000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
1047000
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
50
CY2023Q3 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
199600000
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
2
CY2023Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
10000000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
35
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
107900000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Number Of Positions
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
10
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
44000000
CY2023Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
926000000000
CY2022Q4 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Current
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossCurrent
748000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29519000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28315000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6290000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3500000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
23229000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24815000
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
941000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2800000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
771000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1700000
CY2023Q3 eras Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
9557000
CY2022Q4 eras Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
11523000
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
8501000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
9395000
CY2023Q3 eras Unvested Early Exercised Stock Option Liability
UnvestedEarlyExercisedStockOptionLiability
632000
CY2022Q4 eras Unvested Early Exercised Stock Option Liability
UnvestedEarlyExercisedStockOptionLiability
1690000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
353000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
873000
CY2023Q3 eras Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
17000
CY2022Q4 eras Accrued Property And Equipment Current
AccruedPropertyAndEquipmentCurrent
638000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
151000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
217000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
19211000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24336000
CY2023Q3 eras Share Based Compensation Arrangement By Share Based Payment Award Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesSubjectToRepurchase
515366
CY2022Q4 eras Share Based Compensation Arrangement By Share Based Payment Award Shares Subject To Repurchase
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesSubjectToRepurchase
1115105
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0896
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6238000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5232000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20095000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14729000
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
42803420
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
34381274
eras Operating Leases Cancelable And Non Cancellable Expiration Dates
OperatingLeasesCancelableAndNonCancellableExpirationDates
2032
eras Operating Leases Non Cancelable Expiration Dates
OperatingLeasesNonCancelableExpirationDates
2026
CY2023Q3 us-gaap Lease Cost
LeaseCost
2800000
us-gaap Lease Cost
LeaseCost
8600000
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
us-gaap Operating Lease Cost
OperatingLeaseCost
5700000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
859000
us-gaap Variable Lease Cost
VariableLeaseCost
2900000
CY2022Q3 us-gaap Lease Cost
LeaseCost
2600000
us-gaap Lease Cost
LeaseCost
5100000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
1900000
us-gaap Operating Lease Cost
OperatingLeaseCost
3900000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
701000
us-gaap Variable Lease Cost
VariableLeaseCost
1100000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
24000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
86000
us-gaap Operating Lease Payments
OperatingLeasePayments
4700000
us-gaap Operating Lease Payments
OperatingLeasePayments
585000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y6M10D
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0895
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y3M3D
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2146000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8752000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
9024000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
9170000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
9199000
CY2023Q3 eras Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
44375000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
82666000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
25908000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
56758000
CY2023Q3 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q3 us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Federal Income Tax Expense Benefit Continuing Operations
FederalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q3 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q3 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q3 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2023Q3 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
0
CY2022Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023Q3 us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
us-gaap Income Tax Examination Penalties And Interest Expense
IncomeTaxExaminationPenaltiesAndInterestExpense
0
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-30361000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35489000
us-gaap Net Income Loss
NetIncomeLoss
-95341000
us-gaap Net Income Loss
NetIncomeLoss
-107555000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150450201
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120798322
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150000613
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
120166023
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27248429
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19800563

Files In Submission

Name View Source Status
eras-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062094-index-headers.html Edgar Link pending
0000950170-23-062094-index.html Edgar Link pending
0000950170-23-062094.txt Edgar Link pending
0000950170-23-062094-xbrl.zip Edgar Link pending
eras-20230930.htm Edgar Link pending
eras-20230930.xsd Edgar Link pending
eras-ex10_1.htm Edgar Link pending
eras-ex31_1.htm Edgar Link pending
eras-ex31_2.htm Edgar Link pending
eras-ex32_1.htm Edgar Link pending
eras-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img198692883_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
eras-20230930_def.xml Edgar Link unprocessable
eras-20230930_lab.xml Edgar Link unprocessable
eras-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eras-20230930_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending